Annual report pursuant to Section 13 and 15(d)

Segment Reporting (Segments Reporting) (Details)

v3.21.2
Segment Reporting (Segments Reporting) (Details) - USD ($)
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Segment Reporting Information [Line Items]    
Revenues – external customers $ 2,371,000 $ 1,638,000
Cost of goods sold 1,462,000 703,000
Gross profit 909,000 935,000
Research and Development Expense 9,989,000 3,573,000
General and administrative 22,031,000 11,365,000
Operating loss (31,111,000) (14,003,000)
Interest expense (2,454,000) (2,466,000)
Settlement income 10,200,000  
Interest and other income 152,000 25,000
Consolidated net loss (23,213,000) (16,444,000)
Total assets 146,968,000 94,189,000
Finance lease ROU assets 26,111,000 27,616,000
Fixed assets, net of accumulated depreciation 8,628,000 3,657,000
Intangible assets, net of accumulated amortization 952,000 1,144,000
Amortization of finance lease ROU assets 1,651,000 1,661,000
Depreciation of fixed assets 472,000 282,000
Amortization of intangible assets 291,000 298,000
Operating Segments [Member] | Biopharmaceuticals (iBio, Inc.) [Member]    
Segment Reporting Information [Line Items]    
Revenues – external customers 1,098,000 1,546,000
Revenues – intersegment 1,017,000 793,000
Cost of goods sold 425,000 640,000
Gross profit 1,690,000 1,699,000
Research and Development Expense 2,960,000 492,000
General and administrative 13,429,000 5,355,000
Operating loss (14,699,000) (4,148,000)
Interest expense 0  
Settlement income 10,200,000  
Interest and other income 151,000 24,000
Consolidated net loss (4,349,000) (4,124,000)
Total assets 175,272,000 103,667,000
Fixed assets, net of accumulated depreciation 0  
Intangible assets, net of accumulated amortization 952,000 1,144,000
Amortization of finance lease ROU assets 0  
Depreciation of fixed assets 0 1,000
Amortization of intangible assets 291,000 298,000
Operating Segments [Member] | Bioprocessing (iBio CDMO) [Member]    
Segment Reporting Information [Line Items]    
Revenues – external customers 1,274,000 92,000
Revenues – intersegment 1,307,000 1,665,000
Cost of goods sold 1,037,000 63,000
Gross profit 1,543,000 1,694,000
Research and Development Expense 8,370,000 4,779,000
General and administrative 9,585,000 6,770,000
Operating loss (16,412,000) (9,855,000)
Interest expense (2,454,000) (2,466,000)
Interest and other income 1,000 1,000
Consolidated net loss (18,864,000) (12,320,000)
Total assets 35,721,000 31,868,000
Finance lease ROU assets 26,111,000 27,616,000
Fixed assets, net of accumulated depreciation 8,628,000 3,657,000
Intangible assets, net of accumulated amortization 0  
Amortization of finance lease ROU assets 1,651,000 1,661,000
Depreciation of fixed assets 472,000 281,000
Amortization of intangible assets 0  
Eliminations [Member]    
Segment Reporting Information [Line Items]    
Revenues – intersegment (2,324,000) (2,458,000)
Gross profit (2,324,000) (2,458,000)
Research and Development Expense (1,341,000) (1,698,000)
General and administrative (983,000) (760,000)
Operating loss 0  
Interest expense 0  
Total assets (64,025,000) $ (41,346,000)
Fixed assets, net of accumulated depreciation 0  
Intangible assets, net of accumulated amortization 0  
Amortization of finance lease ROU assets 0  
Depreciation of fixed assets 0  
Amortization of intangible assets $ 0